Iterum Therapeutics (ITRM) Debt to Equity (2018 - 2022)
Historic Debt to Equity for Iterum Therapeutics (ITRM) over the last 5 years, with Q3 2022 value amounting to $0.3.
- Iterum Therapeutics' Debt to Equity rose 423.26% to $0.3 in Q3 2022 from the same period last year, while for Sep 2022 it was $0.3, marking a year-over-year increase of 423.26%. This contributed to the annual value of $0.26 for FY2021, which is 12546.81% up from last year.
- Per Iterum Therapeutics' latest filing, its Debt to Equity stood at $0.3 for Q3 2022, which was up 423.26% from $0.23 recorded in Q2 2022.
- Iterum Therapeutics' Debt to Equity's 5-year high stood at $1.11 during Q1 2021, with a 5-year trough of -$4.63 in Q3 2019.
- Over the past 5 years, Iterum Therapeutics' median Debt to Equity value was $0.24 (recorded in 2022), while the average stood at -$0.31.
- As far as peak fluctuations go, Iterum Therapeutics' Debt to Equity plummeted by 48519.9% in 2020, and later surged by 20474.49% in 2021.
- Quarter analysis of 5 years shows Iterum Therapeutics' Debt to Equity stood at $0.2 in 2018, then tumbled by 359.94% to -$0.51 in 2019, then plummeted by 98.41% to -$1.02 in 2020, then surged by 125.47% to $0.26 in 2021, then rose by 17.73% to $0.3 in 2022.
- Its last three reported values are $0.3 in Q3 2022, $0.23 for Q2 2022, and $0.25 during Q1 2022.